Intarcia and Numab to develop once-yearly therapies in diabetes, obesity and autoimmune indications20.03.2015 09:07
Intarcia Therapeutics, Inc. and Numab AG announced a strategic collaboration. Numab is eligible to receive upfront and contingent milestone payments, as well as royalties on sales. In addition Intarcia has an option to purchase a strategic interest in Numab.
Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. Under the terms of the collaboration, Numab is eligible to receive upfront and contingent milestone payments, as well as tiered single to low double-digit royalties on any sales resulting from collaborative efforts. Intarcia has the option to extend the collaboration beyond the initial assets and targets as well as the opportunity to purchase a strategic interest in Numab AG at a pre-defined time point. Intarcia will be responsible for the development, manufacturing and commercialization of all products stemming from the collaboration.
Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics, commented: “We believe the unique characteristics of Numab’s antibody technology fit perfectly with our disruptive platform technologies, which have the potential to eliminate life-long injections and produce best-in-disease once- or twice-yearly medicines. Now is the time, as we finish our phase 3 program for ITCA 650 in type 2 diabetes, to take this important strategic step to enhance and expand our pipeline. This collaboration reinforces Intarcia’s ongoing priority to develop game-changing therapeutics that address major unmet medical needs such as suboptimal efficacy as well as poor compliance and adherence.”
David Urech Ph. D, CSO and co-CEO of Numab AG, stressed: “This collaboration triggers the development of a new generation of medications that addresses the notorious shortcomings of conventional antibody therapeutics. It reflects Numab’s ambition to partner with companies that share our dedication for true innovation.”